New Trends in Brain Shuttle Peptides

Roger Prades, Meritxell Teixidó, Benjamí Oller-Salvia*

*Autor corresponent d’aquest treball

Producció científica: Article en revista indexadaArticle de revisió (sistemàtica)Avaluat per experts

1 Citació (Scopus)

Resum

The pharmacological treatment of central nervous system diseases faces significant challenges due to the presence of the blood-brain barrier (BBB). This barrier naturally protects the brain and prevents therapeutics from reaching their targets efficiently. However, the BBB allows the passage of nutrients and other molecules that guarantee brain homeostasis through selective transport mechanisms present at the BBB. These mechanisms provide an opportunity for delivering therapeutic agents into the central nervous system using brain shuttles. Here we review the progress of brain shuttle peptide development from 2015 until 2025. We highlight the most utilized peptides and describe trends in strategies to develop new shuttles and enhance their transport efficiency. Additionally, we compared them with other types of brain shuttles and emphasize the progress of peptide shuttles toward clinical translation.

Idioma originalAnglès
Pàgines (de-a)1100-1109
Nombre de pàgines10
RevistaMolecular Pharmaceutics
Volum22
Número3
DOIs
Estat de la publicacióPublicada - 3 de març 2025

Fingerprint

Navegar pels temes de recerca de 'New Trends in Brain Shuttle Peptides'. Junts formen un fingerprint únic.

Com citar-ho